{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T21:48:28Z","timestamp":1795038508915,"version":"4.10.2"},"reference-count":31,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Alabama at Birmingham School of Medicine (UABSOM) COVID-19","award":["AR069516"],"award-info":[{"award-number":["AR069516"]}]},{"name":"Swedish Orphan Biovitrum (SOBI)","award":["AR069516"],"award-info":[{"award-number":["AR069516"]}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR069516"],"award-info":[{"award-number":["AR069516"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>(1) Background: Some severe COVID-19 patients develop hyperinflammatory cytokine storm syndrome (CSS). We assessed the efficacy of anakinra added to standard of care (SoC) in hospitalized COVID-19 CSS patients. (2) Methods: In this single-center, randomized, double-blind, placebo-controlled trial (NCT04362111), we recruited adult hospitalized patients with SARS-CoV-2 infection, evidence of pneumonia, new\/increasing oxygen requirement, ferritin \u2265 700 ng\/mL, and at least three of the following indicators: D-dimer \u2265 500 ng\/mL, platelet count &lt; 130,000\/mm3, WBC &lt; 3500\/mm3 or lymphocyte count &lt; 1000\/mm3, AST or ALT &gt; 2X the upper limit of normal (ULN), LDH &gt; 2X ULN, C-reactive protein &gt; 100 mg\/L. Patients were randomized (1:1) to SoC plus anakinra (100 mg subcutaneously every 6 h for 10 days) or placebo. All received dexamethasone. The primary outcome was survival and hospital discharge without need for intubation\/mechanical ventilation. The data were analyzed according to the modified intention-to-treat approach. (3) Results: Between August 2020 and January 2021, 32 patients were recruited, of which 15 were assigned to the anakinra group, and 17 to the placebo group. Two patients receiving the placebo withdrew within 48 h and were excluded. The mean age was 63 years (SD 10.3), 20 (67%) patients were men, and 20 (67%) were White. At Day 10, one (7%) patient receiving anakinra and two (13%) patients receiving the placebo had died (p = 1.0). At hospital discharge, four (27%) patients receiving anakinra and four (27%) patients receiving the placebo had died. The IL-6 level at enrollment was predictive of death (p &lt; 0.01); anakinra use was associated with decreases in CXCL9 levels. (4) Conclusions: Anakinra added to dexamethasone did not significantly impact the survival of COVID-19 pneumonia patients with CSS. Additional studies are needed to assess patient selection and the efficacy, timing, and duration of anakinra treatment for COVID-19 CSS.<\/jats:p>","DOI":"10.3390\/v15102036","type":"journal-article","created":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T16:58:09Z","timestamp":1696179489000},"page":"2036","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9373-7620","authenticated-orcid":false,"given":"Lesley E.","family":"Jackson","sequence":"first","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitasha","family":"Khullar","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Beukelman","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA"},{"name":"Children\u2019s of Alabama, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Chapleau","sequence":"additional","affiliation":[{"name":"UAB Hospital Pharmacy, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6408-3253","authenticated-orcid":false,"given":"Abhishek","family":"Kamath","sequence":"additional","affiliation":[{"name":"Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2661-3086","authenticated-orcid":false,"given":"Randy Q.","family":"Cron","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA"},{"name":"Children\u2019s of Alabama, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Winn","family":"Chatham","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/art.41285","article-title":"On the Alert for Cytokine Storm: Immunopathology in COVID-19","volume":"72","author":"Henderson","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S2665-9913(21)00011-4","article-title":"COVID-19 cytokine storm: Targeting the appropriate cytokine","volume":"3","author":"Cron","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.41103","article-title":"Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis","volume":"72","author":"Eloseily","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1093\/rheumatology\/keab447","article-title":"Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: A systematic review and meta-analysis","volume":"60","author":"Barkas","year":"2021","journal-title":"Rheumatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"155544","DOI":"10.1016\/j.cyto.2021.155544","article-title":"Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19","volume":"143","author":"Geng","year":"2021","journal-title":"Cytokine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: A cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/annrheumdis-2020-217706","article-title":"Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: Case series","volume":"79","author":"Aouba","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijid.2020.07.081","article-title":"Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab","volume":"99","author":"Smith","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"18951","DOI":"10.1073\/pnas.2009017117","article-title":"Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19","volume":"117","author":"Cauchois","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jaci.2020.11.006","article-title":"Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study","volume":"147","author":"Bozzi","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.4049\/jimmunol.2001126","article-title":"IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study","volume":"206","author":"Franzetti","year":"2021","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/jmv.26473","article-title":"Evaluation of 17 patients with COVID-19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA, and Brescia-COVID respiratory severity scale (BCRSS) scoring systems","volume":"93","author":"Erden","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijid.2020.11.149","article-title":"Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study","volume":"103","author":"Balkhair","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e66125","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of anakinra to prevent respiratory failure in COVID-19","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"Elife"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/art.41422","article-title":"Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series","volume":"72","author":"Sattui","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_21","unstructured":"CORIMUNO-19 Collaborative group (2021). Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): A randomised controlled trial. Lancet Respir. Med., 9, 295\u2013304."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.55730\/1300-0144.5345","article-title":"The efficacy of anakinra compared to standard care of treatment for COVID-19: A meta-analysis","volume":"52","author":"Malik","year":"2022","journal-title":"Turk. J. Med. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2665-9913(21)00216-2","article-title":"Effect of anakinra on mortality in patients with COVID-19: A systematic review and patient-level meta-analysis","volume":"3","author":"Kyriazopoulou","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with COVID-19","volume":"384","author":"Group","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41591-021-01569-2","article-title":"Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41584-021-00694-z","article-title":"Targeting interferon-gamma in hyperinflammation: Opportunities and challenges","volume":"17","author":"Prencipe","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1365-3083.2006.001768.x","article-title":"Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy","volume":"63","author":"Ostrowski","year":"2006","journal-title":"Scand. J. Immunol."},{"key":"ref_28","first-page":"36","article-title":"IFN-gamma, CXCL16, uPAR: Potential biomarkers for systemic lupus erythematosus","volume":"36","author":"Wen","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/iid3.563","article-title":"A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19","volume":"10","author":"Kharazmi","year":"2022","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/s41591-021-01500-9","article-title":"Calming the cytokine storm in COVID-19","volume":"27","author":"Cron","year":"2021","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S2665-9913(21)00353-2","article-title":"Who, what, and when-effective therapy for severe COVID-19","volume":"4","author":"Kelmenson","year":"2022","journal-title":"Lancet Rheumatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/10\/2036\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:03:15Z","timestamp":1760130195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/10\/2036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["v15102036"],"URL":"https:\/\/doi.org\/10.3390\/v15102036","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]}}}